IOL Chemicals & Pharmaceuticals Ltd (IOLCP) — shareholding pattern, promoter holding, financials and share price
About IOL Chemicals & Pharmaceuticals Ltd (IOLCP)
IOL Chemicals & Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as IOLCP and on the BSE under scrip code 524164. Its ISIN is INE485C01029.
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market. [1] It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%. [2]
IOL Chemicals and Pharmaceuticals Limited is an integrated API and specialty chemicals manufacturer producing globally significant volumes of Ibuprofen, Ethyl Acetate, Acetic Anhydride and multiple APIs from an 11‑unit, 180+ acre complex; the company services ~80 countries and combines chemical intermediates with regulated API production across dedicated and multiproduct blocks.
The company uniquely claims to be the world’s only fully backward integrated Ibuprofen producer with 12,000 MT annual capacity, and has materially diversified its pharma mix: non‑Ibuprofen share rose from 18% to 34% over five years, reducing concentration risk and improving revenue quality with multiple regulatory filings across USFDA, EDQM and ANVISA.
Listed peers in Pharmaceuticals: Innova Captab Ltd, Bliss GVS Pharma Ltd, Orchid Pharma Ltd, Zota Health Care Ltd, RPG Life Sciences Ltd, Unichem Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹171.1 a share on 10 Jul 2026, IOL Chemicals & Pharmaceuticals Ltd (IOLCP) was valued at a price-to-earnings ratio of 36.49x against an industry P/E of 36.41x and a price-to-book of 2.98x on a book value of ₹57.5 per share as of Mar 2025. Solomo computes return on equity of 8.16% and return on capital employed of 11.02% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 36.49x
- Industry P/E
- 36.41x
- P/B
- 2.98x
- EPS (TTM)
- ₹4.69
- Book value / share
- ₹57.5
- ROE
- 8.16%
- ROCE
- 11.02%
- ROA
- 5.78%
- Debt / equity
- 0.07x
- Dividend yield
- 0.58%
- EBITDA margin
- 12.04%
- 52-week range
- ₹67.14 – ₹177.8
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, IOL Chemicals & Pharmaceuticals Ltd (IOLCP) reported revenue of ₹2,319 crore, net profit of ₹138 crore and earnings per share of ₹4.69. That compares with revenue of ₹2,079 crore and net profit of ₹101 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹619 crore and net profit ₹53 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 |
| Net profit (₹ cr) | 168 | 139 | 134 | 101 | 138 |
| EPS (₹) | 5.71 | 4.74 | 4.58 | 3.44 | 4.69 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 13.90% | 1.88% | -1.63% | -2.51% |
| Profit growth | - | -22.50% | -15.21% | -24.82% |
| Stock price CAGR | 19% | 4% | 30% | 76% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 62.28% of IOL Chemicals & Pharmaceuticals Ltd (IOLCP) (up 4.8 pp QoQ), foreign institutional investors (FII) hold 4.87% and domestic institutional investors (DII) hold 0.43%. Market capitalisation was ₹5,022 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2002.
Largest disclosed public shareholders in Jun 2026: HUF 1.32%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 62.28% | - | 4.87% | 0.43% | 37.72% |
| Mar 2026 | 57.48% | - | 1.72% | 0.02% | 42.52% |
| Dec 2025 | 52.62% | - | 2.08% | 0.03% | 47.38% |
| Sep 2025 | 52.62% | - | 2.25% | 0.04% | 47.38% |
| Jun 2025 | 52.62% | - | 2.59% | 0.02% | 47.38% |
| Mar 2025 | 52.62% | - | 1.47% | 0.07% | 47.38% |
| Dec 2024 | 52.62% | - | 1.49% | 0.08% | 47.38% |
| Sep 2024 | 48.19% | - | 1.63% | 0.08% | 51.81% |